| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Safranin does not target a specific protein or enzyme. As a phenazinium dye, its utility in staining and as a spectroscopic probe is based on its chemical and photophysical properties.
|
|---|---|
| ln Vitro |
The in vitro activity of Safranin is its function as a spectroscopic probe, indicator, and biological stain. The compound exhibits strong absorbance with a lambda max of 517.0 to 522.0 nm in water. Safranin is used for staining Gram-negative bacteria and has been extensively used in academic research as a spectroscopic probe and indicator.
|
| ln Vivo |
Safranin is not used as a therapeutic agent. Its in vivo utility is limited to research and diagnostic applications as a stain. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro binding assays are not applicable for Safranin as it functions as a dye and spectroscopic probe rather than a drug targeting specific enzymes or receptors. The compound is used in staining protocols where it binds to cellular components.
|
| Cell Assay |
For in vitro cellular experiments, Safranin is used in histological staining procedures, particularly for staining Gram-negative bacteria. The compound provides contrast for the visualization of cellular structures under a microscope.
|
| Animal Protocol |
In vivo animal experiments with Safranin are not typically performed, as the compound is primarily used as an in vitro stain. The compound is intended for research and diagnostic use only.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
...Cat dyes penetrate cells more easily and stain the cell nucleus than anionic dyes. Pharmacokinetic properties of Safranin have not been characterized, as the compound is a research-use dye rather than a drug candidate. The compound has a molecular weight of 350.84-350.85 g/mol and should be stored under appropriate conditions. |
| Toxicity/Toxicokinetics |
Toxicological data for Safranin has not been systematically evaluated, as the compound is intended for research and diagnostic applications only and not for therapeutic use. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References | |
| Additional Infomation |
Safranin O is an organochloride salt with the counterion 3,7-diamino-2,8-dimethyl-5-phenylphenazin-5-onium. It is commonly used for staining Gram-negative bacteria. It can be used as a fluorescent dye and a histological dye. Its molecular structure contains 3,7-diamino-2,8-dimethyl-5-phenylphenazin-5-onium.
See also: Phenyrofranin (note moved to). Safranin (Safranine T, Basic Red 2) is a classical phenazinium dye used as a spectroscopic probe, indicator, and biological stain for Gram-negative bacteria. The compound has no clinical or therapeutic applications. |
| Molecular Formula |
C20H19CLN4
|
|---|---|
| Molecular Weight |
350.84
|
| Exact Mass |
350.129
|
| CAS # |
477-73-6
|
| Related CAS # |
69882-16-2
|
| PubChem CID |
2723800
|
| Appearance |
Purple to black solid powder
|
| Density |
1.00 g/mL at 20 °C
|
| Flash Point |
46 °C
|
| Index of Refraction |
n20/D 1.339
|
| LogP |
1.612
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
25
|
| Complexity |
405
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC2=C(C=C1N)[N+](=C3C=C(C(=CC3=N2)C)N)C4=CC=CC=C4.[Cl-]
|
| InChi Key |
OARRHUQTFTUEOS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18N4.ClH/c1-12-8-17-19(10-15(12)21)24(14-6-4-3-5-7-14)20-11-16(22)13(2)9-18(20)23-17;/h3-11H,1-2H3,(H3,21,22);1H
|
| Chemical Name |
3,7-dimethyl-10-phenylphenazin-10-ium-2,8-diamine;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (71.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.13 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8503 mL | 14.2515 mL | 28.5030 mL | |
| 5 mM | 0.5701 mL | 2.8503 mL | 5.7006 mL | |
| 10 mM | 0.2850 mL | 1.4252 mL | 2.8503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.